Fernández-Montes, Ana
de Velasco, Guillermo
Aguín, Santiago
Farriols, Cristina
Guirado-Risueño, María
Jerviz-Guía, Vanessa G.
Baeza-Nadal, María Victoria
Chicas-Sett, Rodolfo
Fírvida, José Luis
García-Navalón, Francisco
Martín, Patricia
Perezagua-Marín, Carmen
Rodríguez, Dulce
Santamaría, Joan
Saurí, Tamara
Cobo, Manuel
Article History
Accepted: 11 January 2021
First Online: 26 February 2021
Compliance with Ethic Standards
:
: All authors have received compensation from Kyowa Kirin Farmacéutica S.L.U. for service as consultants. Ana Fernández-Montes has received grants from Kyowa Kirin outside the submitted work. José Luis-Fírvida has received compensation from Astra Zeneca, Bristol-Myers Squibb, Lilly, Roche, and Takeda for service as consultant, not related to the submitted work. Guillermo de Velasco has received grants/ personal fees from Pfizer, Roche, Ipsen, Astellas, Bayer, Bristol-Myers Squibb, Novartis, Janssen, Merck Sharp & Dohme, and Merck, outside the submitted work. Santiago Aguín has received personal personal fees from Merck, Merck Sharp & Dohme, and Bristol-Myers Squibb, outside the submitted work. José Luis Fírvida has received compensation from Astra Zeneca, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Roche, and Takeda for service as consultant, not related to the submitted work. María Guirado-Risueño has received personal fees and non-financial support from Kyowa Kirin and Roche and personal fees from Merck Sharp & Dohme, Bristol-Myers Squibb, and Astra Zeneca, outside the submitted work.